FDA Clears Palatin Technologies’ IND Filing to Commence Clinical Studies for … – DigitalJournal.com (press release)

FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for
DigitalJournal.com (press release)
"We are excited about the prospect of advancing PL-3994 into a Phase 2A human trial to treat asthma patients," stated Dr. Carl Spana, Palatin's Chief Executive Officer. "Existing therapies for acute exacerbations of asthma in patients unresponsive to

and more »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.